Biological age diagnostics market seen reaching $5.58B by 2030

The biological age and longevity diagnostics market is projected to grow from $3.31 billion in 2026 to $5.58 billion by 2030, driven by personalized medicine, AI-enabled precision tools and wider use of biomarker testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The market is tied to demand for healthier aging, earlier disease detection and more personalized care. - Growth in biological age testing could push more clinics, researchers and consumers toward biomarker-based tools that go beyond chronological age. - The category may benefit from broader adoption of genomics, multi-omics and wearable diagnostics in routine health assessment.

What happened: - The Business Research Company released a report on the biological age and longevity diagnostics market for 2026-2035. - The market rose from $2.9 billion in 2025 to an estimated $3.31 billion in 2026. - The report puts 2026-2030 growth at a 13.9% CAGR, with the market reaching $5.58 billion by 2030. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - The market’s recent growth has been supported by genomic sequencing in clinical research, preventive care, early disease detection and biomarker-based diagnostic tests. - Biotechnology research on aging, healthcare digitization and integration of electronic health records have also supported expansion. - The report says AI-driven precision medicine platforms, consumer demand for personalized healthspan extension and multi-omics data analytics will further accelerate demand. - Direct-to-consumer longevity testing, real-time biosensors and wearable diagnostic technologies are expected to add momentum. - Key trends include multi-omics integration for biological age prediction, AI-powered longevity models, epigenetic and molecular aging indicators, personalized anti-aging intervention plans, and microbiome and metabolic profiling. - Biological age and longevity diagnostics measure cellular, genetic, metabolic and physiological markers to estimate biological age instead of relying only on chronological age. - The diagnostics are designed to help assess health status, predict disease risk and tailor interventions to improve lifespan and healthspan. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, hotspot infographics, key technology analysis and updated graphics and tables. - The Business Research Company offered a free sample report and full report download links. - More information - The full report

Between the lines: - Personalized medicine is a central demand driver because it uses genetic, molecular and clinical data to match prevention and treatment to the individual. - Biological age diagnostics fit that shift by giving clinicians more granular aging data than age alone can provide. - The report highlights FDA approvals of 16 new personalized treatments for rare diseases in 2023, up from six in 2022, as an example of the broader momentum behind personalized care. - Seven of those approvals were cancer therapies.

What's next: - The market is expected to keep expanding as AI, multi-omics and consumer-facing longevity testing become more common. - More use of epigenetic, molecular and wearable-based tools could make biological age testing a routine part of preventive health and longevity planning. - Asia-Pacific may narrow the gap with North America if adoption of these diagnostics accelerates across the region.

The bottom line: - Biological age diagnostics are moving from niche testing toward a broader precision-health category with strong forecast growth and expanding clinical and consumer use.